Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BOLT with free AI briefings, catalyst countdowns, and dilution alerts.

BOLT · Bolt Biotherapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$15M Cash on Hand
9.4mo Cash Runway
Follow BOLT by email Get an email when BOLT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BOLT, unsubscribe in one click. Privacy

📣 What BOLT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Trastuzumab Imbotolimod (BDC-1001) Metastatic Breast Cancer Phase 2 · NCT05954143 Terminated
BDC-4182 Gastric Cancer Adenocarcinoma Metastatic Phase 1/2 · NCT06921837 Recruiting
Anti-dectin-2 Agonist Monoclonal Antibody… Triple Negative Breast Cancer Phase 1 · NCT06052852 Terminated

Also used in these trials (approved or third-party drugs, not BOLT's own candidates): Nivolumab, Pertuzumab, Cemiplimab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BOLT holds $15M in cash and short-term investments (as of Sep 30, 2026) and burns about $4.8M/quarter from operations, an estimated runway of 9.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 49 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BOLT files for a raise →

👥 Who Owns BOLT

Insiders 23.3% Institutions (26 holders) 36.6% Public and other holders 40.1%
HolderTypeShares% of sharesAs of
Coastlands Capital LP
10% owner
Insider 462,416 17.73% 2026-11-09
Sheila Gujrathi
Chief Strategy Officer, Director · +496 options
Insider 85,821 3.29% 2026-10-23
William P. Quinn
President, CEO and CFO, Director · +1.27M options
Insider 25,384 0.97% 2026-09-16
Grant Yonehiro
Chief Operating Officer · +591,027 options
Insider 17,269 0.66% 2026-09-16
Sarah Nemec
Senior VP, Finance and PAO · +352,496 options
Insider 17,082 0.66% 2026-09-16

Share count 2,607,490 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BOLT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BOLT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.